A NEW GENERATION OF PROGESTERONE RECEPTOR POSITIVE BREAST CANCER THERAPEUTICS: SYNTHESIS AND BIOACTIVITIES

Claudia Hödl[a], Katrin Raunegger[a,b], Wolfgang S.L. Strauss[b], Reinhard Sailer[b], Olaf Kunert[a], Christoph Seger[c], Rudolf Steiner[b], Ernst Haslinger[a], H. Wolfgang Schramm[a]

[a]Institute of Pharmaceutical Sciences, Karl-Franzens-University, Universitätsplatz 1, A-8010 Graz, Austria
[b]Institute for Lasertechnology in Medicine and Metrology at the University of Ulm, Helmholtzstrasse 12, D-89081 Ulm, Germany
[c]Institute of Medical and Chemical Laboratory Diagnostics, University Hospital, A-6020 Innsbruck, Austria

We did show recently [1,2] that functionalized mifepristone derivatives are shuttled into the nucleus of a progesterone receptor (PR) cancer cell line. To allow treatment of PR positive breast cancer tumors, combining the receptor selective anti-progestine mifepristone with well established tumor therapeutics seems promising. In this contribution, we present an approach to functionalize mifepristone (1) with doxorubicin and will discuss the assessed in vitro activities of the reaction product 2.



1 **2**

[1] Hödl, C., Strauss, W.S.L., Sailer, R., Seger, Ch., Steiner, R., Haslinger, E., Schramm, H.W., (2004) A Novel High Affine, and Fluorescent Progesterone Receptor Antagonist. Synthesis and in Vitro Studies. Bioconjugate Chem. **15**, 359-365

[2]Hödl, C., Strauss, W.S.L., Sailer, R., Kunert, O., Seger, Ch., Steiner, R., Haslinger, E., Schramm, H.W., (2004) Development and Bioactivities of Novel Progesterone Receptor positive Breast Cancer therapeutics; Eur. J. Pharm. Sci. **23** (Suppl. 1), 33.